Non-small cell lung (NSCLC) cancer is responsible for approximately 85% of the 221,130 lung cancer cases in the US in 2011. Chemotherapy and chemotherapy with targeted monoclonal antibodies for patients with NSCLC remain modestly effective. Therefore, more effective targeted agents are needed for systemic therapy of different NSCLCs as well as the biomarkers associated with treatment benefit. The association between somatic mutations in the epidermal growth factor receptor (EGFR) and the clinical efficacy of the EGFR tyrosine kinase inhibitors, gefitinib and erlotinib, was discovered in 2004. Subsequent clinical studies done in Japan, China, East Asia, and Europe showed NSCLC patients with EGFR mutations treated with gefitinib or erlotinib have a 2-3 fold greater response and progression-free survival with less toxicity than those treated with platinum-based systemic chemotherapy. Further information is needed about patients with NSCLC and EGFR mutations treated with the different EGFR inhibitors in the US, Europe, and around the world. In addition, defining the mechanisms of resistance, identifying means of overcoming resistance to EGFR inhibitors, and improvements in the inhibitors are needed.
The aims of the study are to prospectively validate the frequency and type of acquired resistance mutations and genomic changes arising in subjects with advanced NSCLC and somatic sensitizing mutations of EGFR treated with EGFR inhibitors. Studies of EGFR mutations in NSCLC patients treated with EGFR inhibitors around the world will define the relationship between EGFR mutations, response to treatment, progression-free survival, and survival in subjects with NSCLC treated with erlotinib and gefitinib in subjects with European ethnic background and those from East Asia. The experiments on different therapeutic approaches in lung cancer cell lines and models of acquired resistance to EGFR inhibitors will be done by studying tumors and tumor cell lines harvested or established from patients with clinical resistance to EGFR tyrosine kinase inhibitors. This will facilitate the development of more effective EGFR inhibitors either alone, or with other tyrosine kinase inhibitors and additional targeted agents.

Public Health Relevance

Patients with lung cancer need more effective targeted agents and more biomarkers associated with their treatment benefit rather than less efficacious empiric combination chemotherapy. The treatment of lung cancer patients with genetic changes or mutations in their epidermal growth factor receptor (EGFR) has changed from empiric chemotherapy to treatment with agents that target the EGFR, gefitinib and erlotinib. The studies in this grant will identify why these agents quit working in some patients and help develop therapies which will work longer or find new drugs that work better than these older agents.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Kim, Kelly Y
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Nishino, M; Jackman, D M; DiPiro, P J et al. (2014) Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy. Clin Radiol 69:841-8
Sacher, Adrian G; Jänne, Pasi A; Oxnard, Geoffrey R (2014) Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. Cancer 120:2289-98
Nishino, Mizuki; Cardarella, Stephanie; Dahlberg, Suzanne E et al. (2013) Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 79:283-8
Nishino, Mizuki; Dahlberg, Suzanne E; Cardarella, Stephanie et al. (2013) Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer 119:3761-8
Nishino, Mizuki; Cardarella, Stephanie; Jackman, David M et al. (2013) RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol 201:W64-71
Nishino, Mizuki; Dahlberg, Suzanne E; Cardarella, Stephanie et al. (2013) Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol 8:1059-68
Chong, Curtis R; Jänne, Pasi A (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19:1389-400
Cardarella, Stephanie; Johnson, Bruce E (2013) The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med 188:770-5
Oxnard, Geoffrey R; Jänne, Pasi A (2013) Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes. Clin Cancer Res 19:1634-6
Cortot, Alexis B; Repellin, Claire E; Shimamura, Takeshi et al. (2013) Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 73:834-43

Showing the most recent 10 out of 37 publications